Real-World Effectiveness of Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma

To analyze the real-world usage pattern, effectiveness and factors associated with the effectiveness of regorafenib in the treatment of patients with Hepatocellular Carcinoma. This retrospective, observational study included clinicopathological and follow-up data of patients with Hepatocellular Carcinoma who were treated with regorafenib from June 2017 to September 2020. Patients with incomplete data were excluded. Overall survival (OS) stratified by combination therapy with programmed cell death ligand-1 (PD-L1) inhibitors, chemotherapy and regorafenib dose was calculated by Kaplan Meier method and log rank test. R software version 4.0 was used for the analysis.

1. Inclusion Criteria:

   1. Must be a pathologically proven Hepatocellular Carcinoma
   2. Must have been treated with regorafenib
   3. Regorafenib must be used after two lines of standard antitumor therapy

2. Exclusion Criteria:

   1. Application is less than one course of treatment with regorafenib
   2. First - or second-line treatment with regorafenib
   3. Patients with multiple primary cancers

Patients with pathologically proven Hepatocellular Carcinoma whose disease progressed after two lines of antitumor therapy were treated with regorafenib alone or in combination.

Clinical data of the patients

At any time

Research needs